Pharma's biotech strategy is pretty clear: Buy companies or license in drugs and technology to get a leg up in the expanding market. But The Wall Street Journal notes that Eli Lilly has taken its own unusual approach--developing new biotech therapies from scratch. That's a slow approach, and one that is likely to take years to prove, or disprove, its utility. Half of Lilly's drugs entering the pipeline this year are biotech drugs, up from 10 percent in 2001. And by 2011, Lilly says it will introduce one new biotech drug each year.
- read The Wall Street Journal's article on Lilly (sub. req.)
Buyouts a sign of industry's health. Report
The Top 5 Buyouts of 2007. Report
Deals and more deals. Report
Lilly buying Icos in $2.1B deal. Report